SCHEMBL3786087

SCHEMBL3786087

CN(C)C(=O)ON1C(=O)[C@@H](NC(=O)O)Cc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PYGL P06737 18/20 0.40
PYGM P11217 16/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763249 0.86 EPHX2 (0.41) PYGLPYGM
SCHEMBL4800980 0.84 PYGL (0.43) PYGLPYGM
SCHEMBL4800991 0.84 PYGL (0.43) PYGLPYGM
SCHEMBL3779609 0.80 AADAT (0.54)
SCHEMBL3785883 0.75 AADAT (0.56) PYGLPYGM
SCHEMBL14193208 0.74 PYGL (0.43) PYGLPYGM
SCHEMBL3771568 0.71 TACR1 (0.34) PYGLPYGM
SCHEMBL4799807 0.71 MTNR1A (0.49) PYGLPYGM
SCHEMBL4799822 0.71 MTNR1A (0.49) PYGLPYGM
SCHEMBL3780570 0.71 NPY1R (0.38) PYGLPYGM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443092-B1 BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS PFIZER (US) 2015-04-08 EP disclosed
US-8183238-B2 Bicyclic and tricyclic compounds as KAT II inhibitors PFIZER INC. (US) 2012-05-22 US disclosed
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors PFIZER INC 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors KAT2A, KAT2B, KAT6B PYGL 4580/4885PYGM 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.